{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T13:01:41Z","timestamp":1773493301877,"version":"3.50.1"},"reference-count":115,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1053\/j.seminoncol.2023.01.003","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T16:56:34Z","timestamp":1675356994000},"page":"439-455","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Airway disorders associated with immune checkpoint inhibitor therapy: Two case reports and a systematic review"],"prefix":"10.1053","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6430-3954","authenticated-orcid":false,"given":"Naoki","family":"Kawakami","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susumu","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinpei","family":"Kajie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rina","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Shimaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Wakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhito","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mai","family":"Sakashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2023.01.003_bib0001","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0002","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0003","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1148\/rg.2019190036","article-title":"Immune checkpoint inhibitor therapy-related pneumonitis: patterns and management","volume":"39","author":"Kalisz","year":"2019","journal-title":"Radiographics"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0004","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00050-2017","article-title":"Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients","volume":"50","author":"Delaunay","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0005","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00408-021-00425-x","article-title":"Lessons from pharmacovigilance: pulmonary immune-related adverse events after immune checkpoint inhibitor therapy","volume":"199","author":"Reese","year":"2021","journal-title":"Lung"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0006","doi-asserted-by":"crossref","first-page":"e00638","DOI":"10.1002\/rcr2.638","article-title":"Eosinophilic airway inflammation and eosinophilic chronic rhinosinusitis during nivolumab and ipilimumab","volume":"8","author":"Watanabe","year":"2020","journal-title":"Respirol Case Rep"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0007","article-title":"Nivolumab-induced diffuse type 2 rhinosinusitis: a case report","author":"Kassem","year":"2021","journal-title":"Asian Pac J Allergy Immunol"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0008","first-page":"e24130","article-title":"Immunotherapy-induced eosinophilic tracheitis","volume":"14","author":"Tellez-Garcia","year":"2022","journal-title":"Cureus"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0009","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1093\/annonc\/mdx455","article-title":"Nivolumab-induced asthma in a patient with non-small-cell lung cancer","volume":"28","author":"Maeno","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0010","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jaip.2020.08.022","article-title":"PD-L1 inhibitor-induced worsening of eosinophilic obstructive lung disease successfully rescued with anti-interleukin 5 receptor (IL-5R) therapy","volume":"9","author":"Wassmer","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0011","doi-asserted-by":"crossref","first-page":"e0868","DOI":"10.1002\/rcr2.868","article-title":"Successful management of severe bronchial asthma exacerbated by anti-PD-L1 treatment: a report of two cases","volume":"9","author":"Sumi","year":"2021","journal-title":"Respirol Case Rep"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0012","doi-asserted-by":"crossref","first-page":"e0835","DOI":"10.1002\/rcr2.835","article-title":"Asthma caused by durvalumab after chemoradiotherapy in two patients with non-small cell lung cancer","volume":"9","author":"Uemura","year":"2021","journal-title":"Respirol Case Rep"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0013","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ejca.2021.07.025","article-title":"Acute exacerbation of asthma induced by combined therapy of programmed death-1 blocker plus lenvatinib in a patient with advanced hepatocellular carcinoma","volume":"156","author":"Wang","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0014","doi-asserted-by":"crossref","first-page":"808","DOI":"10.4103\/jcrt.jcrt_419_21","article-title":"The combination therapy with the cytotoxic T lymphocyte-associated antigen-4 and programmed death 1 antibody-induced asthma in a patient with advanced melanoma","volume":"17","author":"Xu","year":"2021","journal-title":"J Cancer Res Ther"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0015","article-title":"Eosinophilic asthma secondary to adjuvant anti-PD-1 immune checkpoint inhibitor treatment in a melanoma patient","volume":"2022","author":"Kissoonsingh","year":"2022","journal-title":"Case Rep Oncol Med"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0016","doi-asserted-by":"crossref","first-page":"e28339","DOI":"10.1097\/MD.0000000000028339","article-title":"A case of bronchial asthma as an immune-related adverse event of pembrolizumab treatment for bladder cancer: a case report","volume":"101","author":"Hamada","year":"2022","journal-title":"Medicine"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0017","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1177\/00034894211021276","article-title":"Pembrolizumab induced acute persistent airway disease in a patient with recurrent respiratory papillomatosis (RRP)","volume":"131","author":"Marcus","year":"2022","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0018","article-title":"A case series of morbid COPD exacerbations during immune checkpoint inhibitor therapy in cancer patients","volume":"34","author":"Nair","year":"2021","journal-title":"Respir Med Case Rep"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0019","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1177\/0003489420937728","article-title":"Allergic fungal sinusitis imitating an aggressive skull base lesion in the setting of pembrolizumab immunotherapy","volume":"130","author":"Krane","year":"2021","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0020","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2018-227814","article-title":"Allergic bronchopulmonary aspergillosis presumably unmasked by PD-1 inhibition","volume":"12","author":"Donato","year":"2019","journal-title":"BMJ Case Rep"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0021","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1136\/annrheumdis-2018-213857","article-title":"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) induced by immune checkpoint inhibitors","volume":"78","author":"Roger","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0022","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12890-020-01375-5","article-title":"Programmed cell death-1 blockade in kidney carcinoma may induce eosinophilic granulomatosis with polyangiitis: a case report","volume":"21","author":"Harada","year":"2021","journal-title":"BMC Pulm Med"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0023","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMoa2106391","article-title":"Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma","volume":"385","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0024","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1398-9995.2010.02458.x","article-title":"Role of PD-L1 and PD-L2 in allergic diseases and asthma","volume":"66","author":"Singh","year":"2011","journal-title":"Allergy"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0025","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.4049\/jimmunol.0900471","article-title":"An anti-inflammatory role for plasmacytoid dendritic cells in allergic airway inflammation","volume":"183","author":"Kool","year":"2009","journal-title":"J Immunol"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0026","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/eji.201444778","article-title":"Differential control of CD4(+) T-cell subsets by the PD-1\/PD-L1 axis in a mouse model of allergic asthma","volume":"45","author":"McAlees","year":"2015","journal-title":"Eur J Immunol"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0027","doi-asserted-by":"crossref","first-page":"e11380","DOI":"10.1097\/MD.0000000000011380","article-title":"A meta-analysis of the association between CTLA-4 genetic polymorphism and susceptibility of asthma","volume":"97","author":"Zheng","year":"2018","journal-title":"Medicine"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0028","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0029","doi-asserted-by":"crossref","first-page":"FSO608","DOI":"10.2144\/fsoa-2020-0070","article-title":"A retrospective analysis of eosinophilia as a predictive marker of response and toxicity to cancer immunotherapy","volume":"6","author":"Krishnan","year":"2020","journal-title":"Future Sci OA"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0030","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2217\/imt-2020-0265","article-title":"Prognosticating role of serum eosinophils on immunotherapy efficacy in patients with advanced melanoma","volume":"13","author":"Kartolo","year":"2021","journal-title":"Immunotherapy"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0031","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.21037\/jtd-20-3525","article-title":"Peripheral blood eosinophilia may be a prognostic biomarker in non-small cell lung cancer patients treated with immunotherapy","volume":"13","author":"Alves","year":"2021","journal-title":"J Thorac Dis"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0032","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40425-015-0064-2","article-title":"Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis","volume":"3","author":"Bostwick","year":"2015","journal-title":"J Immunother Cancer"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0033","doi-asserted-by":"crossref","first-page":"E43","DOI":"10.1002\/hed.26456","article-title":"Nivolumab-related tracheobronchial chondritis: Extremely rare manifestation of an immune-related adverse effect","volume":"42","author":"Kuba","year":"2020","journal-title":"Head Neck"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0034","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.2169\/internalmedicine.6798-20","article-title":"Tracheobronchial chondritis associated with immune checkpoint blockade","volume":"60","author":"Asoh","year":"2021","journal-title":"Intern Med"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0035","article-title":"Tracheobronchial chondritis as an immune-related adverse event occurring during the administration of nivolumab for recurrent hypopharyngeal squamous cell carcinoma","author":"Someya","year":"2022","journal-title":"Ear Nose Throat J"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0036","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s10637-021-01186-3","article-title":"Relapsing polychondritis after treatment with PD-1 blockade","volume":"40","author":"Ogimoto","year":"2022","journal-title":"Invest New Drugs"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0037","article-title":"Pembrolizumab-associated bronchiolitis in an elderly lung cancer patient required the treatment with an inhaled corticosteroid, erythromycin and bronchodilators","volume":"28","author":"Yamaya","year":"2019","journal-title":"Respir Med Case Rep"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0038","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1111\/1759-7714.13862","article-title":"Durvalumab-induced lesions of bronchiolitis and fully reversible bronchiectasis in a patient with non-small cell lung cancer: a case report","volume":"12","author":"Domblides","year":"2021","journal-title":"Thorac Cancer"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0039","doi-asserted-by":"crossref","first-page":"e571","DOI":"10.3747\/co.26.4859","article-title":"Pembrolizumab-induced obstructive bronchiolitis in a patient with stage IV non-small-cell lung cancer","volume":"26","author":"Blanchard","year":"2019","journal-title":"Curr Oncol"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0040","doi-asserted-by":"crossref","first-page":"49","DOI":"10.4103\/JIPO.JIPO_8_18","article-title":"Bronchiolitis obliterans after combination immunotherapy with pembrolizumab and ipilimumab","volume":"1","author":"Balagani","year":"2018","journal-title":"J Immunother Precis Oncol"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0041","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1016\/j.jtho.2018.09.002","article-title":"Fatal airway inflammation induced by pembrolizumab in a patient with NSCLC","volume":"14","author":"Ogawa","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0042","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1159\/000504968","article-title":"Immunotherapy-induced airway disease: a new pattern of lung toxicity of immune checkpoint inhibitors","volume":"99","author":"Mitropoulou","year":"2020","journal-title":"Respiration"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0043","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1136\/thx.2004.024463","article-title":"Inflammatory cells in the airways in COPD","volume":"61","author":"O'Donnell","year":"2006","journal-title":"Thorax"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0044","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00011-020-01408-z","article-title":"The role of CD8\u2009+\u2009T lymphocytes in chronic obstructive pulmonary disease: a systematic review","volume":"70","author":"Williams","year":"2021","journal-title":"Inflamm Res"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0045","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/ppul.20064","article-title":"Lymphocytic inflammation in childhood bronchiolitis obliterans","volume":"38","author":"Mauad","year":"2004","journal-title":"Pediatr Pulmonol"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0046","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1097\/TP.0000000000001592","article-title":"BOS is associated with increased cytotoxic proinflammatory CD8 T, NKT-like, and NK cells in the small airways","volume":"101","author":"Hodge","year":"2017","journal-title":"Transplantation"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0047","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1164\/ajrccm.152.2.7633715","article-title":"Increase in activated CD8+ cells in bronchoalveolar lavage fluid in patients with diffuse panbronchiolitis","volume":"152","author":"Mukae","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0048","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/cmi.2014.20","article-title":"Impaired CTLA-4 responses in COPD are associated with systemic inflammation","volume":"11","author":"Tan","year":"2014","journal-title":"Cell Mol Immunol"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0049","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1183\/09031936.00141808","article-title":"CTLA4 gene polymorphisms are associated with chronic bronchitis","volume":"34","author":"Zhu","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0050","first-page":"2548","article-title":"CTLA-4 gene polymorphisms and susceptibility to chronic obstructive pulmonary disease","volume":"6","author":"Deng","year":"2013","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0051","doi-asserted-by":"crossref","first-page":"e388","DOI":"10.5001\/omj.2022.90","article-title":"Damaskos C. Inhaled bronchodilators and corticosteroids in the management of bronchiolitis obliterans due to allogenic hematopoietic stem cell transplantation","volume":"37","author":"Georgakopoulou","year":"2022","journal-title":"Oman Med J"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0052","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/CJI.0000000000000174","article-title":"Two cases of sinusitis induced by immune checkpoint inhibition","volume":"40","author":"Dein","year":"2017","journal-title":"J Immunother"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0053","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40425-018-0332-z","article-title":"Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab","volume":"6","author":"Acero Brand","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0054","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.ijom.2018.07.025","article-title":"Drug-induced oral lichenoid reaction during nivolumab therapy","volume":"48","author":"Enomoto","year":"2019","journal-title":"Int J Oral Maxillofac Surg"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0055","doi-asserted-by":"crossref","first-page":"E140","DOI":"10.1002\/lary.28038","article-title":"Pembrolizumab-induced mucositis in a patient with recurrent hypopharynx squamous cell cancer","volume":"130","author":"Pelster","year":"2020","journal-title":"Laryngoscope"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0056","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.12998\/wjcc.v8.i18.4100","article-title":"Management of pembrolizumab-induced steroid refractory mucositis with infliximab: a case report","volume":"8","author":"Dang","year":"2020","journal-title":"World J Clin Cases"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0057","article-title":"Severe multiple simultaneous immune-related adverse events in a patient with head and neck cancer","author":"Aoki","year":"2022","journal-title":"Auris Nasus Larynx"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0058","first-page":"1355","article-title":"Sarcoidosis in a patient with metastatic melanoma sequentially treated with anti-CTLA-4 monoclonal antibody and selective BRAF inhibitor","volume":"32","author":"Wilgenhof","year":"2012","journal-title":"Anticancer Res"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0059","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1111\/bjd.14808","article-title":"Pulmonary sarcoid-like granulomatosis induced by nivolumab","volume":"176","author":"Montaudi\u00e9","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0060","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1159\/000492383","article-title":"Sarcoid-like granulomatosis induced by nivolumab treatment in a lung cancer patient","volume":"11","author":"Noguchi","year":"2018","journal-title":"Case Rep Oncol"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0061","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/cyt.12740","article-title":"Diagnostic yield of broncho-alveolar lavage for pembrolizumab induced sarcoid-like reaction of the lung","volume":"30","author":"Grosse","year":"2019","journal-title":"Cytopathology"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0062","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jtho.2018.04.031","article-title":"Sarcoidosis-like reactions induced by checkpoint inhibitors","volume":"13","author":"Gkiozos","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0063","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ejca.2021.05.041","article-title":"Immune checkpoint inhibitor-associated sarcoidosis: a usually benign disease that does not require immunotherapy discontinuation","volume":"158","author":"Chanson","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0064","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.lungcan.2017.05.002","article-title":"Recurrent dysphasia due to nivolumab-induced encephalopathy with presence of Hu autoantibody","volume":"109","author":"Raskin","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0065","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/CJI.0000000000000172","article-title":"Inflammatory myopathy and axonal neuropathy in a patient with melanoma following pembrolizumab treatment","volume":"40","author":"Diamantopoulos","year":"2017","journal-title":"J Immunother"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0066","first-page":"e1310","article-title":"Acute inflammatory demyelinating polyneuroradiculopathy with ipilimumab in metastatic melanoma: a case report and review of literature","volume":"9","author":"Rupareliya","year":"2017","journal-title":"Cureus"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0067","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1016\/j.jtho.2018.08.2032","article-title":"Bilateral vocal cord paralysis: pembrolizumab-induced delayed-onset toxicity in a patient with Lung Adenocarcinoma","volume":"13","author":"Hamada","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0068","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/CJI.0000000000000310","article-title":"Bilateral vocal cord paralysis due to an immune-related adverse event of nivolumab: a case report","volume":"43","author":"Willegers","year":"2020","journal-title":"J Immunother"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0069","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/CJI.0000000000000323","article-title":"Bilateral vocal cord paralysis due to an immune-related adverse event of nivolumab: a case report","volume":"43","author":"Willegers","year":"2020","journal-title":"J Immunother"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0070","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1007\/s10637-020-00947-w","article-title":"Early-onset meningitis associated with atezolizumab treatment for non-small cell lung cancer: case report and literature review","volume":"38","author":"Ogawa","year":"2020","journal-title":"Invest New Drugs"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0071","first-page":"59","article-title":"Nivolumab-induced immune-mediated neurotoxicity in Hodgkin lymphoma","volume":"33","author":"Lopez","year":"2020","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0072","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2020.01.009","article-title":"A case of severe pharyngeal-cervical-brachial syndrome induced by nivolumab and responding to infliximab therapy","volume":"129","author":"Indini","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0073","article-title":"A case of Guillain-Barr\u00e9 syndrome and Stevens-Johnson syndrome\/toxic epidermal necrosis overlap after pembrolizumab treatment","volume":"9","author":"Oguri","year":"2021","journal-title":"J Investig Med High Impact Case Rep"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0074","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1159\/000510740","article-title":"Immune checkpoint inhibitor-induced polymyositis and myasthenia gravis with fatal outcome","volume":"13","author":"Giglio","year":"2020","journal-title":"Case Rep Oncol"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0075","doi-asserted-by":"crossref","DOI":"10.1136\/bmjno-2019-000028","article-title":"Myasthenia gravis and concurrent myositis following PD-L1 checkpoint inhibitor for non-small cell lung cancer","volume":"2","author":"Phua","year":"2020","journal-title":"BMJ Neurol Open"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0076","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/5126717","article-title":"The terrible triad of checkpoint inhibition: a case report of myasthenia gravis, myocarditis, and myositis induced by cemiplimab in a patient with metastatic cutaneous squamous cell carcinoma","volume":"2020","author":"Jeyakumar","year":"2020","journal-title":"Case Reports Immunol"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0077","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ajem.2021.03.005","article-title":"Immune checkpoint inhibitor-associated myasthenia gravis, myositis, and myocarditis overlap syndrome","volume":"46","author":"Lipe","year":"2021","journal-title":"Am J Emerg Med"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0078","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1177\/1078155220976797","article-title":"Late-onset double-seronegative myasthenia gravis syndrome and myasthenic crisis due to nivolumab use for Hodgkin's lymphoma","volume":"27","author":"Dang","year":"2021","journal-title":"J Oncol Pharm Pract"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0079","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2021-241766","article-title":"Myositis and myasteniform syndrome related to pembrolizumab","volume":"14","author":"Sanchez-Sancho","year":"2021","journal-title":"BMJ Case Rep"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0080","first-page":"151","article-title":"Myasthenia gravis: a rare neurologic complication of immune checkpoint inhibitor therapy","volume":"13","author":"Shames","year":"2022","journal-title":"J Adv Pract Oncol"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0081","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1136\/jnnp.52.10.1121","article-title":"The natural course of myasthenia gravis: a long term follow up study","volume":"52","author":"Oosterhuis","year":"1989","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0082","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1148\/radiol.2020200443","article-title":"Incidence of pseudoprogression during immune checkpoint inhibitor therapy for solid tumors: a systematic review and meta-analysis","volume":"297","author":"Park","year":"2020","journal-title":"Radiology"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0083","doi-asserted-by":"crossref","first-page":"655","DOI":"10.20892\/j.issn.2095-3941.2019.0144","article-title":"The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy","volume":"16","author":"Jia","year":"2019","journal-title":"Cancer Biol Med"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0084","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1097\/CAD.0000000000000664","article-title":"Pseudoprogression with subsequent complete response and severe thrombocytopenia to checkpoint inhibitor immunotherapy in a patient with advanced mucosal melanoma of the sinonasal cavity","volume":"29","author":"Philipp","year":"2018","journal-title":"Anticancer Drugs"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0085","article-title":"Severe tracheal stenosis after first administration of pembrolizumab rescued by Dumon Y-stent in a lung cancer patient","volume":"28","author":"Himeji","year":"2019","journal-title":"Respir Med Case Rep"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0086","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000501157","article-title":"Rapid progression of tracheoesophageal fistula caused by immunotherapy administered after tracheal stent placement","volume":"4","author":"Mizuguchi","year":"2019","journal-title":"Biomed Hub"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0087","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.1016\/j.jtho.2019.02.013","article-title":"Tracheoesophageal fistula caused by successful response to pembrolizumab in a patient with squamous cell lung cancer","volume":"14","author":"Wang","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0088","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1111\/1759-7714.13948","article-title":"Expectoration of tonsillar metastasis of pulmonary pleomorphic carcinoma after pseudoprogression: a case report","volume":"12","author":"Kuge","year":"2021","journal-title":"Thorac Cancer"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0089","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1158\/1078-0432.CCR-16-1741","article-title":"Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1\/PD-L1","volume":"23","author":"Champiat","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0090","doi-asserted-by":"crossref","first-page":"e167","DOI":"10.1002\/ctm2.167","article-title":"Hyperprogression: a novel response pattern under immunotherapy","volume":"10","author":"Han","year":"2020","journal-title":"Clin Transl Med"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0091","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/lary.28042","article-title":"Hyperprogression after one dose of nivolumab in sinonasal cancer: a case report","volume":"130","author":"Xiang","year":"2020","journal-title":"Laryngoscope"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0092","doi-asserted-by":"crossref","DOI":"10.1177\/0145561320931215","article-title":"Metastatic renal cell carcinoma presenting as a rapidly enlarging endotracheal mass due to hyperprogression on anti-PD1 immunotherapy","volume":"100","author":"Hoshal","year":"2021","journal-title":"Ear Nose Throat J"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0093","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.12998\/wjcc.v10.i11.3527","article-title":"Double tracheal stents reduce side effects of progression of malignant tracheoesophageal fistula treated with immunotherapy: a case report","volume":"10","author":"Li","year":"2022","journal-title":"World J Clin Cases"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0094","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/1759-7714.14279","article-title":"Successful immune checkpoint inhibitor-based rechallenge in a patient with advanced esophageal squamous cell cancer: a case report","volume":"13","author":"Yao","year":"2022","journal-title":"Thorac Cancer"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0095","doi-asserted-by":"crossref","first-page":"omaa116","DOI":"10.1093\/omcr\/omaa116","article-title":"Bronchoesophageal fistula formation after three courses of nivolumab for carcinoma of unknown primary with a subgroup of lung squamous cell carcinoma","volume":"2020","author":"Nishiyama","year":"2020","journal-title":"Oxf Med Case Reports"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0096","doi-asserted-by":"crossref","first-page":"e00554","DOI":"10.1002\/rcr2.554","article-title":"Oesophagobronchial perforations after placement of an oesophageal self-expanding metallic stent","volume":"8","author":"Tomiyama","year":"2020","journal-title":"Respirol Case Rep"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0097","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.jtho.2019.06.003","article-title":"Bronchomediastinal fistula during durvalumab therapy after chemoradiotherapy in stage III NSCLC","volume":"14","author":"Sumi","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0098","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.21037\/atm-20-7582","article-title":"Bronchopleural fistula following a video-assisted thoracoscopic surgery lobectomy after neoadjuvant therapy of pembrolizumab: a case report and literature review","volume":"8","author":"Cao","year":"2020","journal-title":"Ann Transl Med"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0099","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/j.cllc.2020.07.010","article-title":"Development of bronchopleural fistula after durvalumab consolidation for stage III non-small-cell lung cancer","volume":"22","author":"Darwin","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0100","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1016\/j.athoracsur.2021.11.063","article-title":"Salvage surgery for bronchopleural fistula due to durvalumab and chemoradiation","volume":"114","author":"Tada","year":"2022","journal-title":"Ann Thorac Surg"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0101","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/s41591-020-01224-2","article-title":"Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial","volume":"27","author":"Cascone","year":"2021","journal-title":"Nat Med"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0102","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.athoracsur.2018.02.030","article-title":"Safety and feasibility of lung resection after immunotherapy for metastatic or unresectable tumors","volume":"106","author":"Bott","year":"2018","journal-title":"Ann Thorac Surg"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0103","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1111\/1759-7714.13697","article-title":"Cohesion between pulmonary artery and bronchus after immune checkpoint inhibitor therapy in a lung cancer patient","volume":"11","author":"Takamori","year":"2020","journal-title":"Thorac Cancer"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0104","doi-asserted-by":"crossref","first-page":"e600","DOI":"10.1097\/SLA.0000000000005233","article-title":"Radical minimally invasive surgery after immuno-chemotherapy in initially-unresectable stage IIIB non-small cell lung cancer","volume":"275","author":"Deng","year":"2022","journal-title":"Ann Surg"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0105","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2500\/aap.2017.38.4085","article-title":"Management of adverse reactions to biologic agents","volume":"38","author":"Isabwe","year":"2017","journal-title":"Allergy Asthma Proc"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0106","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.anai.2021.03.008","article-title":"Hypersensitivity reactions and anaphylaxis to checkpoint inhibitor-monoclonal antibodies and desensitization","volume":"126","author":"Labella","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0107","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.iac.2021.12.006","article-title":"Hypersensitivity reactions and immune-related adverse events to immune checkpoint inhibitors: approaches, mechanisms, and models","volume":"42","author":"Park","year":"2022","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0108","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/jcph.818","article-title":"Evaluation of immunogenicity of nivolumab monotherapy and its clinical relevance in patients with metastatic solid tumors","volume":"57","author":"Agrawal","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0109","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1093\/ajhp\/zxz189","article-title":"Treatment with pembrolizumab after hypersensitivity reaction to nivolumab in a patient with hepatocellular carcinoma","volume":"76","author":"Choi","year":"2019","journal-title":"Am J Health Syst Pharm"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0110","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/CMR.0000000000000710","article-title":"Infusion reaction to nivolumab in a metastatic melanoma patient. Safe switch to another anti-programmed death-1: a case report","volume":"31","author":"N\u00fa\u00f1ez Abad","year":"2021","journal-title":"Melanoma Res"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0111","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/CJI.0000000000000324","article-title":"Laryngeal tuberculosis in a patient on avelumab for metastatic nasopharyngeal carcinoma","volume":"43","author":"Song","year":"2020","journal-title":"J Immunother"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0112","article-title":"A case of non-neutropenic invasive pulmonary aspergillosis under immune checkpoint inhibitor therapy for malignant melanoma","volume":"37","author":"Uchida","year":"2022","journal-title":"Respir Med Case Rep"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0113","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1093\/cid\/ciw539","article-title":"The spectrum of serious infections among patients receiving immune checkpoint blockade for the treatment of melanoma","volume":"63","author":"del Castillo","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0114","doi-asserted-by":"crossref","first-page":"e2697","DOI":"10.1093\/cid\/ciaa802","article-title":"Impact of checkpoint inhibitor immunotherapy, primarily pembrolizumab, on infection risk in patients with advanced lung cancer: a comparative retrospective cohort study","volume":"73","author":"Malek","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.seminoncol.2023.01.003_bib0115","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1136\/thoraxjnl-2021-217260","article-title":"Infections due to dysregulated immunity: an emerging complication of cancer immunotherapy","volume":"77","author":"Morelli","year":"2022","journal-title":"Thorax"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775423000039?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775423000039?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T12:57:55Z","timestamp":1758805075000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775423000039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":115,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S0093775423000039"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2023.01.003","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Airway disorders associated with immune checkpoint inhibitor therapy: Two case reports and a systematic review","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminoncol.2023.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}